ArticleCancer research2014
A preclinical assay for chemosensitivity in multiple myeloma.
Article in Cancer research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Microfluidics and organ-on-a-chip technologies: A systematic review of the methods used to mimic bone marrow.PloS one · 2020Pooled it
- Review
- ELDA: real-time functional drug profiling in acute lymphoblastic leukemia.Frontiers in oncology · 2026Article
- Human preclinical multiple myeloma in vitro models for disease modeling and therapy screening.Journal of biological engineering · 2025Review
- Cancer-on-a-chip for precision cancer medicine.Lab on a chip · 2025Review
- Fabrication of a novel 3D-printed perfusion bioreactor for complex cell culture models.Scientific reports · 2025Article
- Bone-on-a-Chip Systems for Hematological Cancers.Biosensors · 2025Review
- Utilizing 3D Models to Unravel the Dynamics of Myeloma Plasma Cells' Escape from the Bone Marrow Microenvironment.Cancers · 2024Review
- CK1δ and CK1ε Signaling Sustains Mitochondrial Metabolism and Cell Survival in Multiple Myeloma.Cancer research · 2023Article
- Microfluidic-based dynamic BH3 profiling predicts anticancer treatment efficacy.NPJ precision oncology · 2022Article
- Patient-Derived Multiple Myeloma 3D Models for Personalized Medicine-Are We There Yet?International journal of molecular sciences · 2022Review
- CancerCellTracker: a brightfield time-lapse microscopy framework for cancer drug sensitivity estimation.Bioinformatics (Oxford, England) · 2022Article
- Timelapse viability assay to detect division and death of primary multiple myeloma cells in response to drug treatments with single cell resolution.Integrative biology : quantitative biosciences from nano to macro · 2022Article
- Advancing Key Gaps in the Knowledge ofFrontiers in cellular and infection microbiology · 2022Review
- Glutathione levels are associated with methotrexate resistance in acute lymphoblastic leukemia cell lines.Frontiers in oncology · 2022Article
- Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma.JCI insight · 2021Article
- MCL-1 dependency as a novel vulnerability for aggressive B cell lymphomas.Blood cancer journal · 2021Article
- Ex Vivo Models Simulating the Bone Marrow Environment and Predicting Response to Therapy in Multiple Myeloma.Cancers · 2020Review
- A pharmacodynamic model of clinical synergy in multiple myeloma.EBioMedicine · 2020Article
- Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma.Expert opinion on drug metabolism & toxicology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Accurate preclinical predictions of the clinical efficacy of experimental cancer drugs are highly desired but often haphazard. Such predictions might be improved by incorporating elements of the tumor microenvironment in preclinical models by providing a more physiological setting. In generating improved xenograft models, it is generally accepted that the use of primary tumors from patients are preferable to clonal tumor cell lines. Here we describe an interdisciplinary platform to study drug response in multiple myeloma, an incurable cancer of the bone marrow. This platform uses microfluidic technology to minimize the number of cells per experiment, while incorporating three-dimensional extracellular matrix and mesenchymal cells derived from the tumor microenvironment. We used sequential imaging and a novel digital imaging analysis algorithm to quantify changes in cell viability. Computational models were used to convert experimental data into dose-exposure-response "surfaces," which offered predictive utility. Using this platform, we predicted chemosensitivity to bortezomib and melphalan, two clinical multiple myeloma treatments, in three multiple myeloma cell lines and seven patient-derived primary multiple myeloma cell populations. We also demonstrated how this system could be used to investigate environment-mediated drug resistance and drug combinations that target it. This interdisciplinary preclinical assay is capable of generating quantitative data that can be used in computational models of clinical response, demonstrating its utility as a tool to contribute to personalized oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.